Menu
Recruiting NCT05749432

A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors

Phase I Interventional Solid Tumor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Hemay181.
Who it may be relevant to
Registry conditions: Solid Tumor. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Antitumor Efficacy of Hemay181 in Patients With Advanced Solid Tumors

Overview

The study will be conducted in about 51 participants in total. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor efficacy of Hemay181 in patients with advanced solid tumors.

Detailed description

The primary purpose of this study is to evaluate the safety and tolerability of Hemay181 in patients with advanced solid tumors, and to explore the maximum tolerated dose. The secondary purpose is to evaluate the pharmacokinetic profile of Hemay181 in patients with advanced solid tumors and to evaluate the preliminary evaluation of the anti-tumor efficacy of Hemay181.

The study will be conducted in two parts. Part one, trial will be conducted in about 24 subjects to determine safety and tolerability of Hemay181 in patients with advanced solid tumors. Part two, approximately 15-27 additional subjects with advanced solid tumors are included to better define the tolerability and preliminary efficacy of Hemay181.

Interventions

  • Drug Hemay181
    Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.

Primary outcome measures

  • Number of participants with adverse events [Time frame: 3 weeks of treatment]
  • Incidence of dose-limiting toxicity (DLT) in each dose group [Time frame: 3 weeks of treatment]
  • Maximum tolerated dose (MTD) or Maximum climbing dose (MAD) of Hemay181 [Time frame: 3 weeks of treatment]
  • Subsequent recommended doses of Hemay181 [Time frame: 3 weeks of treatment]
Secondary outcome measures (12)
  • Objective Response Rate [Time frame: 3 weeks of treatment]
  • Duration of Response [Time frame: 3 weeks of treatment]
  • Disease Control Rate [Time frame: 3 weeks of treatment]
  • Time to Response [Time frame: 3 weeks of treatment]
  • Progression-Free Survival [Time frame: 3 weeks of treatment]
  • Maximum Plasma Concentration （Cmax） [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]
  • Time to reach maximum concentration （Tmax） [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]
  • Elimination half life(t1/2) [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]
  • Plasma Clearance（CL) [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]
  • Mean Residence Time from 0 to last time of quantifiable concentration(MRT 0-t) [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]
  • Mean Residence Time from 0 to infinite time(MRT 0-∞) [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]
  • Area under the plasma concentration-time curve from 0 to last time of quantifiable concentration(AUC 0-t) [Time frame: 0，0.75, 1.5, 1.75, 2, 2.5, 3.5, 5.5, 9.5, 13.5, 25.5, 49.5, 73.5, 97.5, 121.5 hours post-dose on day 1, and 0，1.5, 2.5 hours post-dose on day 22]

Eligibility criteria

Inclusion criteria

  • Male or female subjects aged 18 to 65 years;
  • Subjects must give informed consent to the study before the study entry and voluntarily sign a written informed consent form;
  • Advanced solid tumors patients that confirmed by pathology (histology or cytology) with adequate standard therapy failure or currently have no effective standard treatment (such as breast, liver, lung, gastric cancer, colorectal cancer, etc.); Standard therapy failure is defined as: patients who have undergone at least 2 lines of standard antineoplastic therapy after recurrence/metastasis (including treatment-naïve stage IV) (if only 1-line therapy is recommended for the tumor, standard 1-line therapy shall prevail), and who have been confirmed by the investigator or have a clear disease progression or are intolerable by the medical history;
  • At least one lesion that can be evaluated by CT/MRI (measurable lesions are required) and meet the reproducible evaluation requirements in RECIST V1.1;
  • At least 4 weeks after the latest treatment (chemotherapy, targeted therapy, immunotherapy, radiotherapy, and/or major surgery, etc.), at least 2 weeks after endocrine therapy, and have recovered from the toxic effects caused by previous treatment to lower than grade 1 (CTCAE version 5.0) \[patients with hair loss (any grade), pigmentation (any grade), peripheral sensory neuropathy (grade ≤2) can be enrolled\];
  • Eastern Cooperative Oncology Group(ECOG) score of 0,1；
  • Life expectancy of at least three months;
  • Adequate bone marrow, liver, kidney function, meeting the following criteria:

ANC≥1.5×10\^9/L, HB≥90g/L, PLT≥75×10\^9/L; ALT≤2.5×ULN, AST≤2.5×ULN with no liver metastasis, or ALT≤5×ULN, AST≤5×ULN with liver metastasis; TBIL≤1.5×ULN; Serum creatinine ≤1.5×ULN；

  • All female and male subjects must agree and commit to the use of a reliable contraceptive regimen for the duration of the study and for at least 12 weeks after at the last dose of test article.

Exclusion criteria

  • Pregnant or lactating women;
  • Patients with known central nervous system metastatic disease;
  • Positive blood for human immunodeficiency virus (HIV antibody); Positive hepatitis B surface antigen and Hepatitis B virus deoxyribonucleic acid (HBV-DNA)>upper limit of normal; Active hepatitis C virus (HCV) infection;
  • Patients with active infection requiring intravenous anti-infective therapy;
  • Patients with a history of irinotecan allergic reactions or previous irinotecan gastrointestinal toxicity ≥ grade 3;
  • Have received drug therapy from other clinical trials within 4 weeks prior to enrollment;
  • Known allergy to the active ingredient or excipients of the test drug;
  • The investigator believes that the subject has any clinical or laboratory abnormalities and is not suitable to participate in this clinical study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Beijing Cancer Hospital — Beijing

Identifiers

NCT: NCT05749432 · HM181ST1S01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗